X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration combines Sosei's leading structure-based drug design platform with PharmEnable’s advanced artificial intelligence-enabled platform to drive novel drug discovery for a second neurological disease target.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Recipient: Sosei Heptares
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration October 10, 2023
Details:
The funds will be used to develop the next generation of small molecule drugs and to advance and expand PharmEnable’s portfolio of wholly owned and co-discovery projects across oncology and neurology targets, as well as supporting further platform R&D.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: MP Healthcare Venture Management
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Series A Financing May 22, 2023
Details:
The strategic collaboration will aim to accelerate drug discovery in neurodegenerative disease, tackling undisclosed targets in a multi-year programme. Denali will be responsible for the further lead optimisation, development, and commercialisation of these molecules.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Denali Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 30, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
